ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.
EP: 1.Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
EP: 2.Currently Available Treatment Options for Patients With R/R DLBCL
Now Viewing
EP: 3.ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
EP: 4.Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
EP: 5.Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
EP: 6.Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)
EP: 7.CAR T-Cell Therapy for Patients With R/R FL
EP: 8.Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Related Videos
Related Content
